Nama's AI scorecard currently rates ACADIA Pharmaceuticals Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ACAD's P/E ratio?

ACADIA Pharmaceuticals trades at a trailing price-to-earnings ratio of 32.7.

When does ACAD report earnings?

ACADIA Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.21.

What is the ACAD price target?

The median analyst price target from 19 analysts is $33.00, with a range of $16.00 – $37.00.

Is ACAD Shariah compliant?

Nama's AAOIFI-style screen reads ACADIA Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

ACADIA Pharmaceuticals (ACAD)

Healthcare · Biotechnology · NASDAQ

ACADIA Pharmaceuticals (ACAD) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.66B, a trailing price-to-earnings ratio of 32.7 and a free-cash-flow yield of 2.9%. Over the most recent reported fiscal year, revenue grew 11.9% and free cash flow per share fell 34.5%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 4.8/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -9.2% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-37.5%

How far the last close sits under the highest price of the past five years.

Market cap	$3.66B
Trailing P/E	32.7
Price / book	2.8
Price / sales	3.2
FCF yield	2.9%
Dividend yield	—
Gross margin	91.1%
Operating margin	7.6%
Net margin	33.4%
Revenue growth (YoY)	+11.9%
Revenue growth (3-yr annual)	+27.5%
EPS growth (YoY)	-39.0%
FCF/share growth (YoY)	-34.5%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ACAD earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.21). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.31	$0.18	+72.2%	$342.29M
Q2 2026	Aug 4, 2026	$0.18	$0.04	+350.0%	$307.96M
Q1 2026	May 6, 2026	$0.02	$0.08	-75.0%	$268.06M
Q4 2025	Feb 25, 2026	$0.14	$0.14	+0.0%	$283.99M

ACAD analyst price target

Median target $33.00 from 19 analysts, ranging $16.00 – $37.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ACAD data on Nama Insights →

ACAD FAQ

Is ACAD a buy?: Nama's AI scorecard currently rates ACADIA Pharmaceuticals Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ACAD's P/E ratio?: ACADIA Pharmaceuticals trades at a trailing price-to-earnings ratio of 32.7.
When does ACAD report earnings?: ACADIA Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.21.
What is the ACAD price target?: The median analyst price target from 19 analysts is $33.00, with a range of $16.00 – $37.00.
Is ACAD Shariah compliant?: Nama's AAOIFI-style screen reads ACADIA Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.